PASITHEA THERAPEUTICS CORP. Deferred Tax Assets, in Process Research and Development
PASITHEA THERAPEUTICS CORP. (KTTA) had Deferred Tax Assets, in Process Research and Development of $4.29 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $4.29M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $2.92M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $1.98M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $592.00K.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $4.29M 10-K · filed 2026-03-30 |
| 2024-12-31 | $2.92M 10-K · filed 2026-03-30 |
| 2023-12-31 | $1.98M 10-K · filed 2025-03-24 |
| 2022-12-31 | $592.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |